nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00001238,"Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders",,Recruiting,Observational,Kidney Cancer; Urologic Malignant Disorders; Renal Cell Carcinoma; Familial Renal Cancer (FRC); Clear Cell Renal Cancer,,,National Cancer Institute (NCI),,5000,1990-12-05,,United States,No,https://clinicaltrials.gov/study/NCT00001238
NCT00033137,"Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts",,Recruiting,Observational,"Kidney Neoplasms; Kidney Cancer; Pneumothorax; FLCN Protein, Human",,,National Cancer Institute (NCI),,950,2002-05-13,,United States,No,https://clinicaltrials.gov/study/NCT00033137
NCT00102544,Electromagnetic Tracking of Devices During Interventional Procedures,Not Applicable,Enrolling by invitation,Interventional,Adenocarcinoma; Prostate Neoplasms; Prostate Cancer; Renal Cell Carcinoma; Von Hippel Lindau Disease,EM Tracking,,National Institutes of Health Clinical Center (CC),,3894,2005-02-23,2026-06-02,United States,No,https://clinicaltrials.gov/study/NCT00102544
NCT01109394,Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies,,Recruiting,Observational,Sarcoma; Endocrine Tumors; Neuroblastoma; Retinoblastoma; Renal Cancer,,,National Cancer Institute (NCI),,6035,2010-04-21,,United States,No,https://clinicaltrials.gov/study/NCT01109394
NCT02012699,Integrated Cancer Repository for Cancer Research,,Recruiting,Observational,Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; Gastrointestinal Stromal Tumors; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; Central Nervous System Tumor; Central Nervous System Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control,,,University of Nebraska,,999999,2013-11-01,2099-12-05,United States,No,https://clinicaltrials.gov/study/NCT02012699
NCT03422198,Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE),Phase 3,Recruiting,Interventional,Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage I Uterine Corpus Cancer; Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Uterine Corpus Carcinosarcoma; Uterine Corpus Sarcoma,Vaginal Cuff Brachytherapy; Short course vaginal cuff brachytherapy,,University of Utah,Huntsman Cancer Institute,188,2018-02-02,2029-10-31,United States,No,https://clinicaltrials.gov/study/NCT03422198
NCT03474497,"UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade",Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Head and Neck Squamous Cell Carcinoma,IL-2; Pembrolizumab; Radiotherapy,,"Megan Daly, MD",Merck Sharp & Dohme LLC,45,2019-05-20,2023-12-05,United States,No,https://clinicaltrials.gov/study/NCT03474497
NCT03592472,"A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)",Phase 3,Recruiting,Interventional,Renal Cell Carcinoma,Pazopanib; Abexinostat; Placebo,,"Xynomic Pharmaceuticals, Inc.",,413,2018-07-17,2028-06-30,China; Italy; Poland; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT03592472
NCT03682289,Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies,Phase 2,Recruiting,Interventional,Clear Cell Renal Cell Carcinoma; Locally Advanced Pancreatic Cancer; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Renal Cell Carcinoma; Metastatic Urothelial Carcinoma; Metastatic Pancreatic Cancer; Stage III Pancreatic Cancer; Stage III Renal Cell Cancer; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Endometrial Cancer; Metastatic Castration-resistant Prostate Cancer,Ceralasertib; Olaparib; Durvalumab,,Rahul Aggarwal,AstraZeneca,89,2019-01-17,2028-03-31,United States,No,https://clinicaltrials.gov/study/NCT03682289
NCT03786796,Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP-1 or Other DNA Repair Gene Mutations (ORCHID),Phase 2,Recruiting,Interventional,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer; Renal Carcinoma; Kidney Cancer Metastatic,Olaparib,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,AstraZeneca,20,2019-06-03,2028-03-05,United States,No,https://clinicaltrials.gov/study/NCT03786796
NCT03810651,Pilot Study of Pencil Beam Scanning Proton Beam Radiation Therapy in Patients With Renal Tumors,Early Phase 1,Recruiting,Interventional,Renal Tumor; Wilms Tumor,Proton beam radiation using pencil beam scanning,,Children's Hospital of Philadelphia,,28,2017-12-26,2027-10-30,United States,No,https://clinicaltrials.gov/study/NCT03810651
NCT03972657,A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression,Phase 1/Phase 2,Recruiting,Interventional,Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC),REGN5678; Cemiplimab,,Regeneron Pharmaceuticals,,345,2019-08-12,2027-11-15,United States,No,https://clinicaltrials.gov/study/NCT03972657
NCT04084067,Indocyanine Green (ICG) Guided Tumor Resection,Phase 1,Recruiting,Interventional,Neoplastic Disease; Solid Tumor,Indocyanine Green,,St. Jude Children's Research Hospital,,230,2020-02-07,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT04084067
NCT04115254,A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART),Not Applicable,Recruiting,Interventional,Pancreas Cancer; Lung Cancer; Renal Cancer; Adrenal Metastases; Prostate Cancer; Liver Metastases; Oligoprogressive Nodal Metastases; Metachronous Nodal Metastases; Synchronous Nodal Metastases; Mesothelioma; Spine Metastases; Brain Metastases; Borderline Resectable Pancreatic Carcinoma,MR-guided Linac,,Dana-Farber Cancer Institute,,397,2019-10-22,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT04115254
NCT04150042,SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives,Phase 1,Recruiting,Interventional,Pancreatic Adenocarcinoma Metastatic; BRCA1 Mutation; BRCA2 Mutation; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; Breast Cancer Metastatic; Breast Cancer Stage IV; Pancreatic Cancer Stage IV; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Adenocarcinoma of the Breast; PALB2 Gene Mutation,Melphalan; BCNU; Vitamin B12B; Vitamin C; Ethanol; Autologous Hematopoietic Stem Cells,,"General Oncology, Inc.","Myriad Genetics, Inc.",10,2021-01-13,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT04150042
NCT04473781,Prospective Study of Interstitial Brachytherapy for Unresectable/Unablatable T1b/T2a Renal Masses,Phase 1/Phase 2,Recruiting,Interventional,Stage I Renal Cell Cancer; Stage II Renal Cell Cancer,Interstitial Radiation Therapy,,Jonsson Comprehensive Cancer Center,,17,2020-07-16,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT04473781
NCT04510597,Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial),Phase 3,Recruiting,Interventional,Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8,Cytoreductive Nephrectomy; Active Comparator,,SWOG Cancer Research Network,National Cancer Institute (NCI),364,2021-03-08,2033-07-05,United States,No,https://clinicaltrials.gov/study/NCT04510597
NCT04575935,Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy,Phase 3,Recruiting,Interventional,Advanced Ovarian Carcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Tumor; Fallopian Tube Serous Neoplasm; Fallopian Tube Transitional Cell Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8,Chemotherapy; Laparotomy; Minimally Invasive Surgery; Quality-of-Life Assessment; Questionnaire Administration,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),580,2020-08-05,2028-12-31,Canada; Italy; Mexico; Netherlands; United States,No,https://clinicaltrials.gov/study/NCT04575935
NCT04620239,Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer,Phase 3,Recruiting,Interventional,Transitional Cell Cancer of Renal Pelvis and Ureter,padeliporfin VTP,,Steba Biotech S.A.,PrimeVigilance; ICON plc,100,2021-03-22,2029-01-25,Austria; France; Germany; Israel; Spain; United States,No,https://clinicaltrials.gov/study/NCT04620239
NCT04654975,Risk Factors and Treatment Options for Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer: a Multicentric Retrospective Cohort Study (METABREC),,Recruiting,Observational,Esophageal Neoplasms; Esophagectomy; Brain Metastases,Esophagectomy for esophageal cancer,,Universitaire Ziekenhuizen KU Leuven,,10000,2020-06-02,2025-03-31,Belgium; France; Ireland; Netherlands; Sweden; United States,No,https://clinicaltrials.gov/study/NCT04654975
NCT04657068,"A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; Metastatic Colorectal Cancer; Pancreatic Ductal Adenocarcinoma; Acinar Cell Carcinoma,ART0380; Gemcitabine; Irinotecan,,Artios Pharma Ltd,,502,2020-12-13,2026-12-05,France; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04657068
NCT04712851,"A Phase II Open-Label, Single Arm Pilot Study to Evaluate the Safety and Efficacy of Pembrolizumab for High-Grade Cervical Intraepithelial Neoplasia",Phase 2,Recruiting,Interventional,Cervical Intraepithelial Neoplasia; Cervical Squamous Cell Carcinoma In Situ; Cervical Squamous Intraepithelial Neoplasia 2,Pembrolizumab,,Jonsson Comprehensive Cancer Center,Merck Sharp & Dohme LLC,25,2021-06-30,2027-01-31,United States,No,https://clinicaltrials.gov/study/NCT04712851
NCT04724018,Combinations of Sacituzumab Govitecan Plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate With Immunotherapy (DAD-IO) Phase I/II Trial,Phase 1/Phase 2,Recruiting,Interventional,Urothelial Cancer; Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Bladder Cancer,Sacituzumab Govitecan (SG); Enfortumab vedotin-ejfv (EV); Pembrolizumab,,Dana-Farber Cancer Institute,Gilead Sciences,106,2021-05-20,2028-05-01,United States,No,https://clinicaltrials.gov/study/NCT04724018
NCT04777994,A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors,Phase 1,Recruiting,Interventional,Advanced Solid Tumor Cancer,ABBV-CLS-484; Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI); Programmed Cell Death-1 (PD-1) Inhibitor,,Calico Life Sciences LLC,,248,2021-03-09,2026-10-05,France; Israel; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04777994
NCT04792463,Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome,,Recruiting,Observational,Uveal Melanoma; Cutaneous Melanoma; BAP1 Gene Mutation; Renal Cell Carcinoma; Mesothelioma; Hepatocellular Carcinoma; Cholangiocarcinoma; Meningioma Atypical,,,Mohamed Abdel-Rahman,,500,2015-03-03,2026-07-01,United States,No,https://clinicaltrials.gov/study/NCT04792463
NCT04851119,"A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Colorectal Carcinoma; Endometrial Carcinoma; Melanoma; Neuroblastoma; Ovarian Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Desmoid Fibromatosis; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Refractory Desmoid Fibromatosis; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Solid Pseudopapillary Neoplasm of the Pancreas; Wilms Tumor,Biospecimen Collection; Dual X-ray Absorptiometry; Tegavivint; X-Ray Imaging,,Children's Oncology Group,National Cancer Institute (NCI),147,2021-11-08,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT04851119
NCT04903873,"An Open-Label, Phase 1/2 Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor; Renal Cell Cancer Metastatic; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Prostate Cancer,EU101,,Eutilex,,110,2021-05-31,2025-12-05,South Korea; United States,No,https://clinicaltrials.gov/study/NCT04903873
NCT04919629,Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion,Phase 2,Recruiting,Interventional,Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Bevacizumab; Biopsy; Biospecimen Collection; Pegcetacoplan; Pembrolizumab; Questionnaire Administration,,Roswell Park Cancer Institute,National Cancer Institute (NCI),60,2023-04-27,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT04919629
NCT04923178,A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies,,Recruiting,Observational,Urothelial Cancer; Bladder Cancer; Genitourinary Cancer; Urogenital Neoplasms; Urogenital Cancer,,,National Cancer Institute (NCI),,1100,2022-10-24,2042-12-01,United States,No,https://clinicaltrials.gov/study/NCT04923178
NCT04981509,"A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer",Phase 2,Recruiting,Interventional,Hereditary Leiomyomatosis and Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma; Sporadic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Atezolizumab; Bevacizumab; Biopsy Procedure; Biospecimen Collection; Bone Scan; Computed Tomography; Computed Tomography with Contrast; Erlotinib; Magnetic Resonance Imaging; Positron Emission Tomography; Sodium Fluoride F-18,,National Cancer Institute (NCI),,65,2022-06-10,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT04981509
NCT04989959,An Exploratory Study of [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma,Phase 1,Recruiting,Interventional,Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma,[18F]PT2385; Positron Emission Tomography/Computed Tomography; Biopsy,,Orhan Kemal Oz,,35,2021-08-18,2027-08-18,United States,No,https://clinicaltrials.gov/study/NCT04989959
NCT05037825,The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors,,Recruiting,Observational,Non-Small-Cell Lung Carcinoma; Malignant Melanoma; Renal Cell Carcinoma; Triple-Negative Breast Cancer,"Checkpoint Inhibitor, Immune",,VastBiome,,800,2021-11-22,2028-09-14,United States,No,https://clinicaltrials.gov/study/NCT05037825
NCT05046080,Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor,,Recruiting,Observational,"Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type",Electronic Health Record Review; Laboratory Biomarker Analysis,,M.D. Anderson Cancer Center,,70,2021-08-06,2026-09-29,United States,No,https://clinicaltrials.gov/study/NCT05046080
NCT05049538,A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancer,,Recruiting,Observational,Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Serous Adenocarcinoma; Malignant Uterine Neoplasm; Uterine Corpus Carcinosarcoma,Biospecimen Collection; Liquid Biopsy; Pap Smear,,M.D. Anderson Cancer Center,,1000,2019-06-18,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT05049538
NCT05064280,"Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases",Phase 2,Recruiting,Interventional,Brain Metastases; Tumor,Pembrolizumab; Lenvatinib,,M.D. Anderson Cancer Center,Eisai Inc.,104,2022-01-20,2028-02-28,United States,No,https://clinicaltrials.gov/study/NCT05064280
NCT05115812,Renal Autotransplantation; Case Series,,Enrolling by invitation,Observational,"Renal Vascular Disease; Nutcracker Syndrome, Renal; Pelvic Trauma; Loin Pain-Hematuria Syndrome; Renal Tumor; Congestion, Venous",Pre-Operative Information; Intra-Operative Data; Post-Operative Data (up to discharge); Short-Term Follow-Up Data,,Methodist Health System,,30,2021-09-15,2024-09-30,United States,No,https://clinicaltrials.gov/study/NCT05115812
NCT05155033,Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma,Phase 2,Recruiting,Interventional,Metastatic Melanoma; Advanced Locoregional Melanoma; Metastatic Renal Cell Carcinoma; Clear Cell Histology,Pembrolizumab; Aldesleukin,,National Cancer Institute (NCI),,78,2022-08-18,2031-09-01,United States,No,https://clinicaltrials.gov/study/NCT05155033
NCT05225428,Video Education With Result Dependent dIsclosure,Not Applicable,Recruiting,Interventional,Genetic Testing; Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Colorectal Cancer; Renal Cancer; Melanoma; Sarcoma,Video Education; Genetic Counseling,,Dana-Farber Cancer Institute,National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI),1020,2022-08-04,2026-09-01,United States,No,https://clinicaltrials.gov/study/NCT05225428
NCT05256225,"A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma",Phase 3,Recruiting,Interventional,Endometrial Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Uterine Corpus Carcinosarcoma,Biospecimen Collection; Carboplatin; Computed Tomography; Echocardiography Test; High-Dose-Rate Vaginal Cuff Brachytherapy; Hyaluronidase-zzxf/Pertuzumab/Trastuzumab; Multigated Acquisition Scan; Paclitaxel; Survey Administration; Trastuzumab/Hyaluronidase-oysk,,National Cancer Institute (NCI),NRG Oncology,360,2022-11-16,2027-10-31,Puerto Rico; South Korea; United States,No,https://clinicaltrials.gov/study/NCT05256225
NCT05267626,"A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma; Non-Small Cell Lung Cancer,AU-007; Aldesleukin; Avelumab; Nivolumab,,"Aulos Bioscience, Inc.",,159,2022-04-04,2026-06-12,Australia; United States,No,https://clinicaltrials.gov/study/NCT05267626
NCT05269381,A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA),Phase 1/Phase 2,Recruiting,Interventional,Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Merkel Cell Carcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Cervical Carcinoma; Locally Advanced Endometrial Carcinoma; Locally Advanced Gastric Adenocarcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hepatocellular Carcinoma; Locally Advanced Lung Non-Small Cell Carcinoma; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Locally Advanced Merkel Cell Carcinoma; Locally Advanced Renal Cell Carcinoma; Locally Advanced Skin Squamous Cell Carcinoma; Locally Advanced Triple-Negative Breast Carcinoma; Locally Advanced Unresectable Breast Carcinoma; Locally Advanced Unresectable Cervical Carcinoma; Locally Advanced Unresectable Gastric Adenocarcinoma; Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma; Locally Advanced Unresectable Renal Cell Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Cervical Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Merkel Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Metastatic Urothelial Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IV Merkel Cell Carcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Skin Squamous Cell Carcinoma; Stage III Cervical Cancer AJCC v8; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Cervical Carcinoma; Unresectable Endometrial Carcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma; Unresectable Head and Neck Squamous Cell Carcinoma; Unresectable Hepatocellular Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma; Unresectable Merkel Cell Carcinoma; Unresectable Renal Cell Carcinoma; Unresectable Skin Squamous Cell Carcinoma; Unresectable Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma,Cyclophosphamide; Neoantigen Peptide Vaccine; Pembrolizumab; Sargramostim,,Mayo Clinic,,36,2022-03-31,2026-02-24,United States,No,https://clinicaltrials.gov/study/NCT05269381
NCT05281471,"A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",Phase 3,Recruiting,Interventional,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma,"olvimulogene nanivacirepvec; Platinum chemotherapy: carboplatin (preferred) or cisplatin; Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin; Bevacizumab (or biosimilar)",,Genelux Corporation,GOG Foundation,186,2022-08-31,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT05281471
NCT05297734,Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer,Not Applicable,Recruiting,Interventional,End of Life; Cancer,Receive technology-based supportive cancer care; Receive redesigned team-based supportive cancer care,,Stanford University,Patient-Centered Outcomes Research Institute,2996,2022-06-24,2028-02-28,United States,No,https://clinicaltrials.gov/study/NCT05297734
NCT05316155,Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer,Phase 1/Phase 2,Recruiting,Interventional,"Urinary Bladder Neoplasms; Receptors, Fibroblast Growth Factor",Erdafitinib Intravesical Delivery System,,"Janssen Research & Development, LLC",,262,2022-04-11,2029-10-01,Canada; Germany; Israel; Japan; Netherlands; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05316155
NCT05319015,A Phase II Study of the Safety and Efficacy of Neoadjuvant Lenvatinib and Pembrolizumab in Patients With Renal Cell Carcinoma and IVC Tumor Thrombus,Phase 2,Recruiting,Interventional,Renal Cell Carcinoma,"Neoadjuvant Lenvatinib; Neoadjuvant Pembrolizumab; Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection; Adjuvant Pembrolizumab",,University of Texas Southwestern Medical Center,,30,2023-01-06,2026-08-05,United States,No,https://clinicaltrials.gov/study/NCT05319015
NCT05361720,Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC),Phase 2,Recruiting,Interventional,Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Cabozantinib; Ipilimumab; Nivolumab,,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI); United States Department of Defense,54,2022-12-01,2026-07-01,United States,No,https://clinicaltrials.gov/study/NCT05361720
NCT05366881,"cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse",,Recruiting,Observational,Brain Cancer; Breast Cancer; Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Esophageal Cancer; Stomach Cancer; Head and Neck Cancer; Hepatobiliary Cancer; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cancer; Sarcoma; Thyroid Cancer,,,"Adela, Inc",,7000,2022-05-03,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05366881
NCT05381597,Combination of 5-Fluorouracil and Calcipotriene in the Treatment of Superficial Basal Cell Carcinomas and Squamous Cell Carcinomas in Situ,Phase 2/Phase 3,Recruiting,Interventional,Superficial Basal Cell Carcinoma; Squamous Cell Carcinoma in Situ,Combination cream of 5-fluorouracil and calcipotriene; 5-fluorouracil cream,,Boston University,,200,2022-10-15,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT05381597
NCT05388773,Phase II Trial of Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer,Phase 2,Recruiting,Interventional,Oropharynx Cancer,therapeutic conventional surgery; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy; Cisplatin; Carboplatin,,Heath Skinner,,150,2022-07-20,2030-12-31,United States,No,https://clinicaltrials.gov/study/NCT05388773
NCT05433142,A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma,Phase 1,Recruiting,Interventional,Clear Cell Renal Cell Carcinoma,XmAb819,,"Xencor, Inc.",,95,2022-06-13,2027-11-05,United States,No,https://clinicaltrials.gov/study/NCT05433142
NCT05479812,A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors,Phase 1,Recruiting,Interventional,Metastatic Solid Tumor; Advanced Solid Tumor,WTX-124; pembrolizumab,,"Werewolf Therapeutics, Inc.",Merck Sharp & Dohme LLC,150,2022-05-20,2026-07-31,United States,No,https://clinicaltrials.gov/study/NCT05479812
NCT05536141,"A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors",Phase 1,Recruiting,Interventional,Clear Cell Renal Cell Carcinoma; Solid Tumors,casdatifan; Cabozantinib; Zimberelimab,,"Arcus Biosciences, Inc.",,302,2022-10-26,2027-07-05,Australia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT05536141
NCT05584670,"A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,SAR445877; Cetuximab; ADG126; Bevacizumab; Nivolumab; Ipilimumab,,Sanofi,,542,2022-11-29,2028-06-28,Chile; Israel; Netherlands; Spain; United States,No,https://clinicaltrials.gov/study/NCT05584670
NCT05600777,"A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)",Phase 3,Recruiting,Interventional,Cough; Refractory Chronic Cough,BLU-5937; Placebo,,Bellus Health Inc. - a GSK company,,975,2022-12-05,2027-03-23,Australia; Canada; China; Czechia; Germany; India; Japan; New Zealand; Slovakia; South Korea; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05600777
NCT05614739,"FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations",Phase 1,Recruiting,Interventional,Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms,LOXO-435; Pembrolizumab; enfortumab vedotin,,Eli Lilly and Company,,535,2023-01-12,2027-06-05,Australia; Canada; China; France; Germany; Israel; Italy; Japan; Netherlands; Norway; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05614739
NCT05641935,Multi-Modality Detection of RCC Recurrence Post Ablation,Phase 2,Recruiting,Interventional,Recurrent Renal Cell Carcinoma; Renal Cell Carcinoma,Sulfur Hexafluoride Lipid Microspheres; Contrast-Enhanced Ultrasound; Computed Tomography; Magnetic Resonance Imaging; Electronic Health Record Review,,john eisenbrey,National Cancer Institute (NCI),210,2022-11-03,2027-08-31,United States,No,https://clinicaltrials.gov/study/NCT05641935
NCT05663710,Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC,Phase 1/Phase 2,Recruiting,Interventional,Advanced Cancer; Clear Cell Renal Cell Carcinoma,177Lu girentuximab; Nivolumab; Cabozantinib; ArabinoFuranosylGuanine [18F]F-AraG,,M.D. Anderson Cancer Center,Telix Pharmaceuticals Limited; United States Department of Defense,100,2023-06-30,2027-10-30,United States,No,https://clinicaltrials.gov/study/NCT05663710
NCT05665361,A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC),Phase 1/Phase 2,Recruiting,Interventional,Advanced Clear Cell Renal Carcinoma (Ccrcc); Papillary Renal Cell Carcinoma (Prcc),Sasanlimab; Palbocicilib,,National Cancer Institute (NCI),,100,2024-04-24,2027-06-01,United States,No,https://clinicaltrials.gov/study/NCT05665361
NCT05700461,Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Renal Cell Carcinoma,Phase 1,Recruiting,Interventional,Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer,Implantable Microdevice (IMD),,Wenxin Xu,,5,2023-04-24,2026-03-05,United States,No,https://clinicaltrials.gov/study/NCT05700461
NCT05703854,"Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma",Phase 1/Phase 2,Recruiting,Interventional,Advanced Renal Cell Carcinoma; Advanced Mesothelioma; Advanced Osteosarcoma,CAR.70/IL15-transduced CB-derived NK cells; Fludarabine phosphate; Cyclophosphamide,,M.D. Anderson Cancer Center,,50,2023-03-29,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT05703854
NCT05874921,"uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto",,Recruiting,Observational,"Urothelial Carcinoma; Urothelial Carcinoma Recurrent; Urothelial Carcinoma Ureter; Urothelial Carcinoma Ureter Recurrent; Urothelial Cancer of Renal Pelvis; Urothelial Carcinoma of the Renal Pelvis and Ureter; Carcinoma, Transitional Cell; Transitional Cell Carcinoma of Renal Pelvis",Jelmyto (mitomycin) for pyelocalyceal solution,,UroGen Pharma Ltd.,,400,2023-11-17,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT05874921
NCT05896839,A Phase 2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers,Phase 1/Phase 2,Recruiting,Interventional,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Metastatic Basal Cell Carcinoma; Metastatic Carcinoma in the Skin; Metastatic Melanoma; Metastatic Merkel Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Unresectable Basal Cell Carcinoma; Unresectable Melanoma; Unresectable Merkel Cell Carcinoma; Unresectable Skin Squamous Cell Carcinoma,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Ipilimumab; Kidney Biopsy; Magnetic Resonance Imaging; Nivolumab; Prednisone; Sirolimus,,National Cancer Institute (NCI),,16,2024-07-24,2027-01-31,United States,No,https://clinicaltrials.gov/study/NCT05896839
NCT05899361,A Pilot Study of a Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest for Surgical Dissection Within Urologic Regions of Interest.,Not Applicable,Recruiting,Interventional,Urologic Cancer; Urologic Neoplasms; Bladder Cancer; Prostate Cancer; Testicular Cancer; Kidney Cancer; Urethral Cancer; Penile Cancer,Electromagnetic Guided Laparoscopy; Ultrasound,,Dana-Farber Cancer Institute,Siemens Medical Solutions,10,2023-08-30,2026-12-25,United States,No,https://clinicaltrials.gov/study/NCT05899361
NCT05931393,"Phase 2, Open-label, Single Cohort, Multicenter Trial for Sequential Treatment of High Dose Cabozantinib on/After Progression on Cabozantinib Monotherapy in Advanced Renal Cell Carcinoma (Seq-Cabo)",Phase 2,Recruiting,Interventional,RCC; Renal Cell Carcinoma,Cabozantinib 80 MG,,University of Texas Southwestern Medical Center,Exelixis,18,2023-12-20,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT05931393
NCT05969496,Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX),Phase 2,Recruiting,Interventional,Renal Cancer; Kidney Cancer; Renal Cell Carcinoma; Inferior Vena Cava Thrombosis,Axitinib; Pembrolizumab,,"University of Colorado, Denver",Cancer League of Colorado,17,2023-12-04,2029-11-05,United States,No,https://clinicaltrials.gov/study/NCT05969496
NCT06005818,Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC),Phase 2,Recruiting,Interventional,Renal Cell Carcinoma,Pembrolizumab injection,,University of Alabama at Birmingham,,100,2024-01-01,2028-09-05,United States,No,https://clinicaltrials.gov/study/NCT06005818
NCT06026410,"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer); Non Clear Cell Renal Cell Carcinoma (nccRCC),Darlifarnib; Cabozantinib; Adagrasib,,"Kura Oncology, Inc.",Mirati Therapeutics Inc.,300,2023-10-18,2027-04-05,France; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06026410
NCT06040762,"The ""Get Moving Trial"": A Phase I/II RCT of Home-Based (P)Rehabilitation With ExerciseRx in Bladder Cancer and Upper Tract Urothelial Cancer",Not Applicable,Recruiting,Interventional,Bladder Cancer; Urothelial Carcinoma; Upper Tract Urothelial Carcinoma; Renal Pelvis and Ureter Urothelial Carcinoma,Best Practice; Exercise Intervention; App-Based Intervention; App-Based Intervention; Interview; Wearable Activity Tracker; Physical Performance Testing; Questionnaire Administration,,University of Washington,Bladder Cancer Advocacy Network,128,2023-12-19,2026-10-30,United States,No,https://clinicaltrials.gov/study/NCT06040762
NCT06101290,Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER),Not Applicable,Recruiting,Interventional,Prostate Cancer; Oligoprogressive; Urothelial Carcinoma; Renal Cell Carcinoma,Ablative local therapy,,"University of California, Davis",National Cancer Institute (NCI),150,2023-10-05,2031-01-05,United States,No,https://clinicaltrials.gov/study/NCT06101290
NCT06222593,A Phase I/II Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with Receptor Tyrosine Kinase Inhibitor Resistant Renal Cell Carcinoma,Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Renal Cell",Bicalutamide in combination with Sunitinib,,State University of New York at Buffalo,,28,2024-10-01,2027-07-01,United States,No,https://clinicaltrials.gov/study/NCT06222593
NCT06234605,"A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma",Phase 1,Recruiting,Interventional,Renal Cell Carcinoma,HC-7366; Belzutifan,,"HiberCell, Inc.",Merck Sharp & Dohme LLC,80,2024-04-29,2027-11-05,United States,No,https://clinicaltrials.gov/study/NCT06234605
NCT06242470,"A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer; Breast Cancer; Ovarian Cancer; Esophageal Squamous Cell Cancer (SCC),MGC026 Dose Escalation; MGC026 Dose for Expansion,,MacroGenics,,250,2024-03-06,2028-10-05,Australia; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06242470
NCT06265285,"Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",Phase 2,Recruiting,Interventional,Advanced Esophageal Squamous Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Esophageal Carcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Carcinoma; Locally Advanced Urothelial Carcinoma; Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Metastatic Colorectal Carcinoma; Metastatic Cutaneous Melanoma; Metastatic Esophageal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Cutaneous Melanoma; Unresectable Esophageal Squamous Cell Carcinoma; Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Home Health Encounter; Nivolumab; Patient Monitoring; Questionnaire Administration,,Mayo Clinic,,50,2024-04-30,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT06265285
NCT06270706,"A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab",Phase 1,Recruiting,Interventional,Metastatic Solid Tumor,PLN-101095; Pembrolizumab,,"Pliant Therapeutics, Inc.",,77,2023-08-30,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT06270706
NCT06305767,A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005),Phase 1/Phase 2,Recruiting,Interventional,Bladder Cancer,Pembrolizumab; Intismeran autogene; Placebo; Enfortumab Vedotin; Surgery (RC plus PLND),,Merck Sharp & Dohme LLC,"ModernaTX, Inc.",230,2024-03-28,2031-10-20,Australia; Canada; Chile; Colombia; France; Germany; Italy; New Zealand; Peru; Poland; South Korea; Spain; Sweden; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06305767
NCT06332755,"A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC); Renal Cell Carcinoma(RCC); Urothelial Carcinoma; Malignant Melanoma,Phase 1a: LB-LR1109; Phase 1b: LB-LR1109 and Atezolizumab,,LG Chem,,76,2024-06-05,2028-03-05,United States,No,https://clinicaltrials.gov/study/NCT06332755
NCT06447103,89Zr-DFO-GmAb PET/CT vs Contrast-Enhanced CT for Detection of Recurrent Clear Cell Renal Cell Carcinoma After Surgery,Phase 2,Recruiting,Interventional,Clear Cell Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer,Biospecimen Collection; Bone Scan; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration; Zirconium Zr 89 Girentuximab,,Jonsson Comprehensive Cancer Center,Telix Pharmaceuticals (Innovations) Pty Limited,91,2024-08-06,2030-12-01,United States,No,https://clinicaltrials.gov/study/NCT06447103
NCT06500455,Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases,Phase 3,Recruiting,Interventional,Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Digestive System Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Computed Tomography; Fractionated Stereotactic Radiation Therapy; Magnetic Resonance Imaging; Stereotactic Radiosurgery,,NRG Oncology,,269,2024-12-12,2028-06-30,Canada; Hong Kong; United States,No,https://clinicaltrials.gov/study/NCT06500455
NCT06562192,"Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; HR+/HER2- Ductal and Lobular Breast Cancer; Triple Negative Breast Cancer; Colorectal Cancer,[68Ga]Ga-NNS309; [177Lu]Lu-NNS309,,Novartis Pharmaceuticals,,162,2024-10-15,2031-01-16,Belgium; Canada; France; Germany; Israel; Italy; Netherlands; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06562192
NCT06639074,MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT),Phase 2,Recruiting,Interventional,Advanced Fallopian Tube Carcinoma; Advanced Fallopian Tube High Grade Serous Adenocarcinoma; Advanced Ovarian Carcinoma; Advanced Ovarian Carcinosarcoma; Advanced Ovarian Clear Cell Adenocarcinoma; Advanced Ovarian Endometrioid Adenocarcinoma; Advanced Ovarian High Grade Serous Adenocarcinoma; Advanced Primary Peritoneal Carcinoma; Advanced Primary Peritoneal High Grade Serous Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Mixed Cell Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma,Biopsy; Biospecimen Collection; Computed Tomography; Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed; Leukapheresis; Magnetic Resonance Imaging; Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine; Placebo Administration; Tetanus and Diphtheria Toxoids Adsorbed,,Mayo Clinic,,78,2024-11-08,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT06639074
NCT06677190,A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary or Clear Cell Carcinoma of Other Gynecologic Origin,Phase 2,Recruiting,Interventional,Ovarian Cancer; Ovarian Carcinoma; Endometrial Cancer; Uterine Cancer; Cervical Cancer; Vulvar Cancer; Gynecologic Cancer; Vaginal Cancer,Belzutifan,,Dana-Farber Cancer Institute,Merck Sharp & Dohme LLC,32,2024-12-20,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06677190
NCT06704724,A PHASE 1 OPEN-LABEL STUDY OF PF-07985045 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS,Phase 1,Recruiting,Interventional,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",PF-07985045; Gemcitabine; Nab-paclitaxel; Cetuximab; Fluorouracil; Oxaliplatin; Leucovorin; Bevacizumab; Pembrolizumab; Sasanlimab; pemetrexed; Cisplatin; Paclitaxel; Carboplatin; PF-07284892,,Pfizer,,190,2024-12-10,2029-03-11,Japan; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06704724
NCT06732401,A Randomized Phase III Trial of Checkpoint Blockade in Lung Cancer Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR),Phase 3,Recruiting,Interventional,Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8,Biospecimen Collection; Ceralasertib; Computed Tomography; Durvalumab; Echocardiography Test,,National Cancer Institute (NCI),,630,2025-08-07,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT06732401
NCT06764095,CAST-AI: Cystectomy After Systemic Therapy With ADC and Immunotherapy,Phase 4,Recruiting,Interventional,Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8,Biospecimen Collection; Computed Tomography; Cystectomy; Enfortumab Vedotin; Local Therapy; Magnetic Resonance Imaging; Pembrolizumab; Positron Emission Tomography; Questionnaire Administration; Ureterectomy,,Mayo Clinic,,75,2025-01-08,2034-12-31,United States,No,https://clinicaltrials.gov/study/NCT06764095
NCT06770855,A Phase II Study of Total Consolidative Metastasis-and-primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC).,Not Applicable,Not yet recruiting,Interventional,Renal Cell Carcinoma,Total consolidative MPDT,,Abramson Cancer Center at Penn Medicine,,23,2025-11-11,2028-09-05,United States,No,https://clinicaltrials.gov/study/NCT06770855
NCT06794229,"A Phase II, Open-label, Single-arm Study of nEoadjuvant Zanzalintinib (XL092) Plus nivoLumab in Patients With lOcally Advanced and/or inopeRable clEar Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis (EXPLORE-RCC)",Phase 2,Recruiting,Interventional,Locally Advanced Renal Cell Carcinoma,Zanzalintinib; Nivolumab,,Qian Qin,Exelixis; University of Texas,69,2025-10-30,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT06794229
NCT06805825,A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit,Phase 1,Recruiting,Interventional,Gastrointestinal Stromal Tumors; Small-cell Lung Cancer; Adenoid Cystic Carcinoma; Uveal Melanoma; Neuroendocrine Tumors; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma,NN3201,,"Novelty Nobility, Inc.",,67,2025-02-03,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT06805825
NCT06863311,EXACT: Randomized Phase II Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC,Phase 2,Recruiting,Interventional,Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma,XL092; Nivolumab,,Karie Runcie,Exelixis; Columbia University,70,2025-12-05,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT06863311
NCT06866262,Phase I/II Trial of Inulin Gel in Combination With Ipilimumab and Nivolumab in Advanced Renal Cell Carcinoma [ICON Trial],Phase 1/Phase 2,Recruiting,Interventional,Locally Advanced Clear Cell Renal Cell Carcinoma; Locally Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8,Biopsy; Biospecimen Collection; Computed Tomography; Inulin; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Questionnaire Administration,,University of Michigan Rogel Cancer Center,United States Department of Defense,55,2025-08-15,2031-08-01,United States,No,https://clinicaltrials.gov/study/NCT06866262
NCT06910657,"A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer; Melanoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Breast Cancer; Sarcoma; Bladder Cancer; Lung Cancer; Prostate Cancer; Cervical Cancers; Head and Neck Cancers; Adrenal Gland Tumors,IDOV-Immune (oncolytic vaccinia virus),,"ViroMissile, Inc.",,78,2025-08-25,2027-05-31,Australia; United States,No,https://clinicaltrials.gov/study/NCT06910657
NCT06919666,Phase Ib/II Study of NT219 in Combination With Pembrolizumab or Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC),Phase 1/Phase 2,Recruiting,Interventional,Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma,NT219,,"University of Colorado, Denver",Purple Biotech Ltd.,29,2025-06-12,2031-02-05,United States,No,https://clinicaltrials.gov/study/NCT06919666
NCT06940518,Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma,Phase 2,Recruiting,Interventional,Ivonescimab; Clear Cell Renal Carcinoma,Ivonescimab,,M.D. Anderson Cancer Center,Strategic Alliance; Summit Therapeutics,40,2025-07-02,2030-01-19,United States,No,https://clinicaltrials.gov/study/NCT06940518
NCT06948552,A Phase II Study on Photodynamic Diagnosis of Urological Cancer in the Upper Urinary Tract Using Fluorescence Endoscopy With Cystoscopy and Ureteroscopy With 5-ALA,Phase 2,Not yet recruiting,Interventional,Upper Tract Urothelial Carcinoma,5-Aminolevulinic acid Hydrochloride (Gliolan®),,Henry Ford Health System,,10,2025-05-05,2026-03-05,United States,No,https://clinicaltrials.gov/study/NCT06948552
NCT06966024,"An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer",Phase 1,Recruiting,Interventional,Renal Cell Carcinoma; Urothelial Carcinoma; Castration-resistant Prostate Cancer,DCC-2812,,"Deciphera Pharmaceuticals, LLC",,60,2025-08-27,2029-02-05,United States,No,https://clinicaltrials.gov/study/NCT06966024
NCT07010978,R34 Study 2 - Pilot RCT Testing the Effectiveness of RCCs,Not Applicable,Recruiting,Interventional,Opioid Use Disorder,Recovery Community Center Participation; Enhance Treatment as Usual,,Massachusetts General Hospital,National Institute on Drug Abuse (NIDA),128,2025-08-20,2027-04-15,United States,No,https://clinicaltrials.gov/study/NCT07010978
NCT07043608,A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors,Phase 2,Not yet recruiting,Interventional,"Clear Cell Renal Cell Cancer (ccRCC); Clear Cell Renal Carcinoma; Clear Cell Renal Cell Carcinoma Metastatic; Clear Cell Renal Cancer; Bone Metastases of a Malignant Tumor; Clear Cell Renal Cell Carcinoma; Bone, Metastatic Cancer; Metastatic Cancer; Metastatic Renal Cell Carcinoma; Metastases to Bone",Zanzalintinib; Investigator Choice of Bone Strengthening Agents (BSA); Non-Investigational Radiation Therapy (RT); Bone Scan; Computerized tomography (CT) Scan,,"Kelly Fitzgerald, MD",Exelixis,20,2025-09-30,2029-09-30,United States,No,https://clinicaltrials.gov/study/NCT07043608
NCT07072234,Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma,Phase 1,Recruiting,Interventional,Clear Cell Carcinoma; Phase 1; Growth Factor,Lymphodepleting chemotherapy; Dexamethasone; Fludarabine; Cyclophosphamate; TGFBR-2 KO CD70 CAR NK,,M.D. Anderson Cancer Center,,30,2025-09-25,2030-02-01,United States,No,https://clinicaltrials.gov/study/NCT07072234
NCT07077083,A Pilot Study of 89Zr-girentuximab for PET Imaging in Residual or Recurrent Post Ablative Tumors in Patients With Renal Cell Carcinoma.,Phase 2,Not yet recruiting,Interventional,Clear Cell Renal Cell Carcinoma (ccRCC); ccRCC,89Zr-Girentuximab,,Massachusetts General Hospital,"Telix Pharmaceuticals, Ltd",10,2025-08-01,2028-08-01,United States,No,https://clinicaltrials.gov/study/NCT07077083
NCT07092566,"Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial",Phase 3,Recruiting,Interventional,Renal Carcinoma; Nephrectomy / Methods; Pain Management,Ropivacaine HCL; Exparel; Epinephrine; Clonidine HCL; Ketorolac,,Wake Forest University Health Sciences,Atrium Health Levine Cancer Institute,170,2025-11-14,2027-10-05,United States,No,https://clinicaltrials.gov/study/NCT07092566
NCT07124000,Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study,,Recruiting,Observational,"Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Gall Bladder Cancer; Gastrointestinal Stromal Tumour; Head and Neck Cancer; Liver Cancer; Melanoma; Mouth Cancer; Nasopharangeal Cancer; Neuroendocrine, Gastrointestinal Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cell Carcinoma; Salivary Gland Cancer; Sarcoma; Small Cell Lung Cancer; Testicular Cancer; Throat Cancer; Thyroid Cancer; Urethral Cancer; Vaginal Cancer; Vulvar Cancer",Trastuzumab deruxtecan,,AstraZeneca,,100,2025-09-18,2028-03-30,United States,No,https://clinicaltrials.gov/study/NCT07124000
